TY - JOUR
T1 - Hypertension pharmacological treatment in adults
T2 - A world health organization guideline executive summary
AU - Al-Makki, Akram
AU - DiPette, Donald
AU - Whelton, Paul K.
AU - Murad, M. Hassan
AU - Mustafa, Reem A.
AU - Acharya, Shrish
AU - Beheiry, Hind Mamoun
AU - Champagne, Beatriz
AU - Connell, Kenneth
AU - Cooney, Marie Therese
AU - Ezeigwe, Nnenna
AU - Gaziano, Thomas Andrew
AU - Gidio, Agaba
AU - Lopez-Jaramillo, Patricio
AU - Khan, Unab I.
AU - Kumarapeli, Vindya
AU - Moran, Andrew E.
AU - Silwimba, Margaret Mswema
AU - Rayner, Brian
AU - Sukonthasan, Apichard
AU - Yu, Jing
AU - Saraffzadegan, Nizal
AU - Reddy, K. Srinath
AU - Khan, Taskeen
N1 - Publisher Copyright:
© 2021 The Authors.
PY - 2022/1/1
Y1 - 2022/1/1
N2 - Hypertension is a major cause of cardiovascular disease and deaths worldwide especially in low- and middle-income countries. Despite the availability of safe, well-tolerated, and cost-effective blood pressure (BP)-lowering therapies, <14% of adults with hypertension have BP controlled to a systolic/diastolic BP <140/90 mm Hg. We report new hypertension treatment guidelines, developed in accordance with the World Health Organization Handbook for Guideline Development. Overviews of reviews of the evidence were conducted and summary tables were developed according to the Grading of Recommendations, Assessment, Development, and Evaluations approach. In these guidelines, the World Health Organization provides the most current and relevant evidence-based guidance for the pharmacological treatment of nonpregnant adults with hypertension. The recommendations pertain to adults with an accurate diagnosis of hypertension who have already received lifestyle modification counseling. The guidelines recommend BP threshold to initiate pharmacological therapy, BP treatment targets, intervals for follow-up visits, and best use of health care workers in the management of hypertension. The guidelines provide guidance for choice of monotherapy or dual therapy, treatment with single pill combination medications, and use of treatment algorithms for hypertension management. Strength of the recommendations was guided by the quality of the underlying evidence; the tradeoffs between desirable and undesirable effects; patient's values, resource considerations and cost-effectiveness; health equity; acceptability, and feasibility consideration of different treatment options. The goal of the guideline is to facilitate standard approaches to pharmacological treatment and management of hypertension which, if widely implemented, will increase the hypertension control rate world-wide.
AB - Hypertension is a major cause of cardiovascular disease and deaths worldwide especially in low- and middle-income countries. Despite the availability of safe, well-tolerated, and cost-effective blood pressure (BP)-lowering therapies, <14% of adults with hypertension have BP controlled to a systolic/diastolic BP <140/90 mm Hg. We report new hypertension treatment guidelines, developed in accordance with the World Health Organization Handbook for Guideline Development. Overviews of reviews of the evidence were conducted and summary tables were developed according to the Grading of Recommendations, Assessment, Development, and Evaluations approach. In these guidelines, the World Health Organization provides the most current and relevant evidence-based guidance for the pharmacological treatment of nonpregnant adults with hypertension. The recommendations pertain to adults with an accurate diagnosis of hypertension who have already received lifestyle modification counseling. The guidelines recommend BP threshold to initiate pharmacological therapy, BP treatment targets, intervals for follow-up visits, and best use of health care workers in the management of hypertension. The guidelines provide guidance for choice of monotherapy or dual therapy, treatment with single pill combination medications, and use of treatment algorithms for hypertension management. Strength of the recommendations was guided by the quality of the underlying evidence; the tradeoffs between desirable and undesirable effects; patient's values, resource considerations and cost-effectiveness; health equity; acceptability, and feasibility consideration of different treatment options. The goal of the guideline is to facilitate standard approaches to pharmacological treatment and management of hypertension which, if widely implemented, will increase the hypertension control rate world-wide.
KW - Blood pressure
KW - Cardiovascular disease
KW - Hypertension
KW - Pharmacotherapy
UR - http://www.scopus.com/inward/record.url?scp=85120951920&partnerID=8YFLogxK
U2 - 10.1161/HYPERTENSIONAHA.121.18192
DO - 10.1161/HYPERTENSIONAHA.121.18192
M3 - Article
C2 - 34775787
AN - SCOPUS:85120951920
SN - 0194-911X
VL - 79
SP - 293
EP - 301
JO - Hypertension
JF - Hypertension
IS - 1
ER -